



ASO VISUAL ABSTRACT

ASO Visual Abstract: Surgical Outcomes for Cancer Patients Undergoing Elective Surgery after Recovering from Mild to Moderate SARS-CoV-2 Infection

Anai N. Kothari, MD¹, Sandra R. DiBrito, MD¹, J. Jack Lee, PhD², Abigail S. Caudle, MD³, Mark W. Clemens, MD⁴, Vijaya N. Gottumukkala, MD⁵, Matthew H. G. Katz, MD¹, Anaeze C. Offodile, MD⁴, Abhineet Uppal, MD⁶ on behalf of D3CODE Team, and George J. Chang, MD, MS⁶

¹Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; ²Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX; ³Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX; ⁵Department of Anesthesia and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX; ⁶Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston, TX

A wait time of 20 days after recovery from mild to moderate SARS-CoV-2 infection appears to be safe for cancer patients undergoing low-risk elective surgery.

Patients requiring inpatient treatment of COVID-19 before surgery are at increased risk for adverse events (<https://doi.org/10.1245/s10434-021-10291-9>).

